Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-16Clinical Trial Update: Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial assessing Silicon Phthalocyanine 4 with photodynamic therapy in recurrent cutaneous T-cell lymphoma including mycosis fungoide…
-
CLINICAL_TRIALS trial_result · 2019-04-11Clinical Trial Update: Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL [Phase 3]
A Phase 3 trial comparing KW-0761 (mogamulizumab) to vorinostat in relapsed/refractory cutaneous T-cell lymphoma has completed and results w…
-
FDA approval · 2018-12-11FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZOLINZA (vorinostat) from Merck Sharp & Dohme LLC.
-
FDA approval · 2018-11-27FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Istodax (romidepsin) from Celgene Corporation. The action updates regulatory labeling for the dr…
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) [Phase 2]
Phase 2 trial update for NM-IL-12 in Cutaneous T-Cell Lymphoma undergoing total skin electron beam therapy (TSEBT).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies [Phase 2]
Phase 2 trial of Deoxycoformycin (pentostatin) in lymphoid malignancies completed, studying Peripheral T-cell Lymphoma and Cutaneous T-cell …
-
FDA approval · 2018-09-04FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's original-application generic of Bexarotene for cutaneous T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-08-20Clinical Trial Update: Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 trial of selinexor in relapsed or refractory PTCL or CTCL; study terminated with posted results in 2018.
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A [Phase 4]
Phase 4 clinical trial update evaluating photopheresis as an interventional therapy for cutaneous T-cell lymphoma, specifically mycosis fung…
-
CLINICAL_TRIALS trial_result · 2018-08-16Clinical Trial Update: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating liposomal doxorubicin followed by bexarotene for cutaneous T-cell lymphoma has completed with posted resul…
-
FDA approval · 2018-07-25FDA Approved: BEXAROTENE — Original Application (Upsher-Smith Laboratories, Inc.)
FDA approved an Original Application for bexarotene from Upsher-Smith Laboratories, Inc., signaling the availability of a generic bexarotene…
-
CLINICAL_TRIALS trial_result · 2018-07-09Clinical Trial Update: Lenalidomide Maintenance Post-debulking in Advanced CTCL [Phase 3]
A Phase 3 trial evaluating lenalidomide maintenance after debulking in advanced cutaneous T-cell lymphoma was terminated.
-
FDA approval · 2018-05-08FDA Approved: BEXAROTENE — Original Application (ANI Pharmaceuticals, Inc.)
ANI Pharmaceuticals received FDA approval for a generic bexarotene through an Original Application (ANDA). The product is indicated for the …
-
CLINICAL_TRIALS trial_result · 2018-03-16Clinical Trial Update: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) [Phase 3]
Phase 3 trial comparing Brentuximab Vedotin to physician's choice in CD30-positive cutaneous T-cell lymphoma completed with posted results.
-
CLINICAL_TRIALS withdrawal · 2018-03-15Clinical Trial Update: Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma [EARLY_Phase 1]
A Phase 1 trial evaluating radiation therapy in combination with durvalumab for tumor-stage Cutaneous T-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides [Phase 1, Phase 2]
A Phase 1/2 trial comparing low-dose total skin electron beam therapy with vorinostat versus TSEBT alone in mycosis fungoides was terminated…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas [Phase 2]
Phase II open-label study of ixazomib (MLN9708) in relapsed/refractory cutaneous and peripheral T-cell lymphomas has completed with results …
-
CLINICAL_TRIALS research · 2017-11-13Clinical Trial Update: Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases [NA]
This clinical-trial update reviews the mechanisms by which phototherapy and photochemotherapy exert therapeutic effects in skin diseases. It…
-
CLINICAL_TRIALS trial_result · 2017-10-02Clinical Trial Update: Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating alefacept in relapsed or refractory cutaneous T-cell lymphoma and peripheral T-cell non-Hodgkin's lymphoma…
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma [Phase 4]
Phase 4 trial update reporting how often carbohydrate metabolism disorders occur in bexarotene-induced hypertriglyceridemia associated with …
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas [Phase 2]
Phase II study of PLM60 for relapsed cutaneous T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level [Phase 2]
Phase 2 trial results of brentuximab vedotin (SGN-35) in patients with mycosis fungoides/cutaneous T-cell lymphoma with variable CD30 expres…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) [Phase 2]
A Phase 2 clinical trial evaluating oral vorinostat (SAHA) for advanced cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fun…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
A Phase 2 study evaluating total skin electron beam therapy (12 Gy) for stage IB-IIIA mycosis fungoides has been terminated, with results po…